SynthesisBMC infectious diseases2026
Influenza vaccine effectiveness according to frailty status in adults aged ≥ 50 years: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOlder adults with influenza have an elevated risk of adverse clinical outcomes. Influenza vaccine effectiveness (VE) is generally lower in this age group due to several factors. Frailty has been identified as a potential modifier of VE, but the literature on this topic is fragmented.
methodsA systematic review of studies evaluating frailty and influenza VE in adults aged ≥ 50 years. Databases were searched from inception to September 2025. The primary outcomes were laboratory-confirmed influenza (LCI), influenza-related hospitalization, and influenza-associated mortality. Random-effects models with restricted maximum likelihood estimation and Hartung-Knapp adjustment were applied when pooling was appropriate. Effect sizes were reported as odds ratios (ORs) with 95% confidence intervals (CIs).
resultsEight studies with 262,952 pooled participants were included. The prevalence of frailty ranged from 14.3% to 36.4%, with a pooled estimate of 24.3% (95% CI, 19.0%-30.4%; I²=99.8%). Four test-negative studies were pooled for LCI cases. Vaccination was associated with reduced odds of LCI (pooled OR, 0.53; 95% CI, 0.37-0.76; I²=4.0%), with a 95% prediction interval of 0.30-0.96. Stratified analyses showed pooled ORs of 0.43 (95% CI, 0.24-0.75) and 0.66 (95% CI, 0.35-1.25) in non-frail and frail individuals, respectively; no statistically significant effect modification was detected (p = 0.10). Hospitalization and mortality outcomes were not pooled because of heterogeneity. The certainty of evidence was low for LCI and very low for other outcomes.
conclusionsInfluenza vaccination protected against LCI across frailty strata, though study heterogeneity requires cautious interpretation, and estimates were less precise for frail individuals. The elevated risk of adverse clinical outcomes in this age group supports immunization, and current data do not justify withholding vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.